Share This Page
Drug Price Trends for TRULANCE
✉ Email this page to a colleague
Average Pharmacy Cost for TRULANCE
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| TRULANCE 3 MG TABLET | 65649-0003-30 | 18.05422 | EACH | 2025-09-17 |
| TRULANCE 3 MG TABLET | 65649-0003-30 | 18.77934 | EACH | 2025-09-15 |
| TRULANCE 3 MG TABLET | 65649-0003-30 | 18.05706 | EACH | 2025-08-20 |
| TRULANCE 3 MG TABLET | 65649-0003-30 | 18.05486 | EACH | 2025-07-23 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
TRULANCE Market Analysis and Financial Projection
Market Analysis and Price Projections for TRULANCE (Plecanatide)
Overview of TRULANCE and Its Indication
TRULANCE (plecanatide) is approved by the FDA for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. It was developed by Synergy Pharmaceuticals, later acquired by the pharmaceutical company Bausch Health.
Approved in 2017, TRULANCE is a guanylate cyclase-C (GC-C) agonist that enhances intestinal fluid secretion, promoting bowel movements. As a late-entry drug in the constipation segment, it faces competition from established drugs such ass linaclotide (Linzess) and fiber-based therapies.
Market Size and Growth Drivers
The global market for drugs treating CIC and IBS-C has shown steady growth, driven by increased diagnosis rates, aging populations, and favorable reimbursement policies.
- The CIC and IBS-C markets are estimated to generate sales of approximately $1.75 billion globally in 2022.
- The segment is projected to grow at a compound annual growth rate (CAGR) of around 4.5-6% over the next five years, reaching $2.4 billion by 2027.
Factors influencing this growth include increasing awareness of functional gastrointestinal disorders and expanding outpatient diagnosis.
Competitive Landscape
TRULANCE's main rivals include:
- Linzess (linaclotide): Launched in 2012, with global sales exceeding $600 million in 2022.
- Viberzi (eluxadoline): Approved for IBS-D but competes indirectly.
- Bulk fiber and lifestyle modifications: Account for significant portions of the market but lack drug-specific revenue.
Other entrants include plecanatide competitors under development and generic options.
Pricing and Reimbursement Dynamics
Current Pricing:
- The average wholesale price (AWP) for TRULANCE is approximately $470–$520 per month for a typical prescription.
- Insurance coverage and pharmacy benefit managers (PBMs) influence net prices, often reducing the effective reimbursement rates.
Reimbursement:
- TRULANCE has favorable coverage in major payers, including Medicare Part D and commercial insurers.
- Reimbursement policies rely on negotiated discounts, affecting net market access.
Price Projections
Factors affecting future pricing include patent expiration, market competition, and regulatory developments.
Patent Status
- The basic patent for plecanatide (U.S. patent number 8,793,153) expires in 2028.
- Patent cliffs typically induce price erosion, with generic entry historically leading to 40-60% price reductions within two years.
Price Trend Scenarios
- Base Case (no significant patent challenges): Prices remain stable with slight downward pressure of 5-10% annually due to market maturation and renewal of formulary listings.
- Optimistic Scenario (delayed generic entry or market exclusivity extension): Prices stabilize around current levels for an additional 2-3 years, with minimal decline.
- Pessimistic Scenario (early patent challenges or rapid generic entry): Prices decline by 40-50% within 1-2 years post-patent expiry.
Revenue and Market Share Projections
Assuming sales volume growth of 3-5% annually, current prices, and market share gains driven by clinical advantages or formulary placement:
| Year | Estimated Market Share | Average Price | Projected Sales |
|---|---|---|---|
| 2023 | 15% | $510 | $250 million |
| 2024 | 18% | $485 | $330 million |
| 2025 | 20% | $460 | $400 million |
| 2026 | 20-22% | $440 | $450 million |
| 2027 | 20-23% | $420 | $480 million |
Note: These estimates exclude the impact of generic entry post-2028.
Impacts of Regulatory Changes and Future Development
- FDA initiatives promoting new therapies for gastrointestinal disorders may influence pricing strategies.
- Development of combination therapies may alter market dynamics.
- Expanded indications (e.g., pediatric use) could increase volume but may also introduce pricing pressures.
Key Takeaways
- The U.S. market for CIC and IBS-C is valued at approximately $1.75 billion, with expected growth to $2.4 billion by 2027.
- TRULANCE’s current price is around $470–$520 monthly, with a stable market share.
- Patent expiration in 2028 could trigger significant price erosion unless extended or protected by new formulation patents.
- Price declines of 40-50% are likely within two years post-patent expiry due to generic competition.
- Market share growth depends on formulary positioning, clinical differentiation, and payer acceptance.
FAQs
1. How does TRULANCE compare to its main competitor, linaclotide?
TRULANCE has similar efficacy and safety profiles but may differ in dosing frequency and side effect profiles. Price differences and formulary placement influence market share advantage.
2. What could delay generic entry for plecanatide?
New patents, patent extensions, or litigation strategies can delay generic competition beyond 2028.
3. Can TRULANCE’s price increase post-approval?
Price increases are primarily constrained by payer negotiations, competitive pressures, and regulatory policies targeting drug pricing.
4. What is the primary driver for TRULANCE’s future sales growth?
Market share gains via formulary access, expanded indications, and increasing diagnosis rates.
5. How might regulatory policies influence TRULANCE’s market?
Drug pricing reforms and biosimilar regulations could impose cost containment measures that suppress price growth and market profitability.
References
- IQVIA, "Pharmaceutical Market Estimates," 2022.
- FDA, "Drug Approvals and Patent Data," 2017–2023.
- Bausch Health Investor Relations, 2022.
- Market Research Future, "Gastrointestinal Therapeutics Market," 2022.
- Medscape, "Constipation Treatment Market," 2023.
More… ↓
